Skip to main content
. Author manuscript; available in PMC: 2013 Jul 26.
Published in final edited form as: N Engl J Med. 2012 Jan 19;366(3):207–215. doi: 10.1056/NEJMoa1105358

Figure 4. Acceleration of Growth of Nonmelanoma Skin Tumors in Mice with BRAF Inhibition.

Figure 4

Panel A shows the number of palpable tumors arising over time in mice treated with the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA), the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), the BRAF inhibitor PLX4720 (PLX) (25 mg per kilogram of body weight per day), and the MEK inhibitor PD184352 (PD) (25 mg per kilogram per day). Each cohort consisted of six mice, and the mean number of tumors per mouse is shown. I bars represent standard deviations. Panel B shows the results at 90 days after mice were treated with four different regimens.